Daiichi Sankyo chief executive elected NPC chairman of the Board

pharmafile | November 19, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |  Daiichi Sankyo 

The National Pharmaceutical Council (NPC) has announced that Daiichi Sankyo president and chief executive John Gargiulo has been elected chairman of its Board of directors.

Gargiulo has served on NPC’s Board since 2007, most recently as vice chair. He has more than 25 years of pharma industry experience and has been instrumental in shaping the company’s US commercial operations, particularly its cardiovascular business.

“For many years, John has been committed to fostering NPC’s growth as a leading healthcare policy research organisation,” said NPC president Dan Leonard. “We’re looking forward to his leadership as chairman. He brings a strong track record of accomplishment from Daiichi Sankyo and a keen understanding of the issues facing our industry and actionable ideas for change.”

Advertisement

Gargiulo added: “As chairman, I’m looking forward to leading NPC as it continues to move forward on issues related to balancing the needs of patients with the population, the value of pharmaceuticals, and the use of real-world evidence.”

The NPC Board also elected Jeff Huth, senior VP, Managed Markets, Boehringer Ingelheim to serve as its vice chair, and Anne Whitaker, president, North America Pharmaceuticals, Sanofi, as Treasurer. Rich Fante, president, US Business & Regional VP, Americas, AstraZeneca, is the outgoing chair and will remain active on NPC’s Board.

Related Content

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics

AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …

The Gateway to Local Adoption Series

Latest content